Nordea Investment Management AB Increases Stock Holdings in Cencora, Inc. $COR

Nordea Investment Management AB lifted its holdings in shares of Cencora, Inc. (NYSE:COR) by 4.6% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,210,644 shares of the company’s stock after acquiring an additional 52,693 shares during the period. Nordea Investment Management AB owned approximately 0.62% of Cencora worth $373,823,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Baader Bank Aktiengesellschaft raised its stake in shares of Cencora by 318.5% during the 2nd quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock valued at $1,300,000 after buying an additional 3,300 shares during the last quarter. Focus Partners Wealth raised its position in Cencora by 25.8% during the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after acquiring an additional 1,171 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Cencora by 947.5% in the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after acquiring an additional 232,539 shares during the period. Fiduciary Alliance LLC purchased a new stake in Cencora in the 2nd quarter worth approximately $262,000. Finally, Martin Capital Partners LLC grew its stake in shares of Cencora by 205.2% during the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after purchasing an additional 2,544 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity

In related news, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 20,317 shares of company stock valued at $7,009,260. 10.80% of the stock is currently owned by insiders.

Cencora Price Performance

Cencora stock opened at $342.11 on Tuesday. Cencora, Inc. has a 52-week low of $233.61 and a 52-week high of $377.54. The firm has a market capitalization of $66.37 billion, a price-to-earnings ratio of 43.03, a PEG ratio of 1.60 and a beta of 0.66. The company has a fifty day simple moving average of $349.92 and a 200-day simple moving average of $318.78. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter in the prior year, the company earned $3.34 EPS. Cencora’s revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is presently 30.19%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on COR shares. TD Cowen increased their price target on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Mizuho raised their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a report on Monday, December 29th. Evercore ISI set a $400.00 price objective on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, Robert W. Baird set a $392.00 target price on Cencora in a research report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $379.50.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.